Carcinogenesis, Vol. 24, No. 4, 665-671,
April 2003
© 2003 Oxford University Press
CANCER BIOLOGY |
Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer
1 Department of Neurology, University of Erlangen-nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany
2 Molecular Toxicology, Division of Biomedical Sciences, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London SW7 2AZ, UK
3 JBUEC, Department of Biology, University of York, York YO1 5DD, UK
4 Centre for Clinical Pharmacology, Kinikum der Johann Wolfgang Goethe Universität, Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt am Main, Germany
5 To whom correspondence should be addressed at: Institute of Physiology and Experimental Pathophysiology, Universitätsstrasse 17, D-91054 Erlangen, Germany Email: maihoefner{at}physiologie1.uni-erlangen.de
Elevated expression of cyclooxygenase-2 (COX-2), the inducible isoform of prostaglandin H synthase, has been found in several human cancers, including colorectal cancer (CRC). This appears as a rationale for the chemopreventive effects of non-steroidal anti-inflammatory drugs in CRC. However, the reason for COX-2 overexpression is not fully understood. In cell culture experiments, COX-2 can be induced by proinflammatory cytokines, such as interleukin (IL)-1beta and IL-6. A crucial step in this signalling pathway is thought to be activation of transcription factor NF-
B. Based on these findings, we hypothesized an association between COX-2 overexpression and expression of IL-1beta, IL-6 and the NF-B subunit p65 in human CRC. To test the hypothesis, we performed immunohistochemistry for the respective antigens on colorectal cancer specimens, obtained by surgical resections from 21 patients with CRC. Immunohistochemical results were confirmed by examination of protein levels in tissue lysates and nuclear extracts using western blotting. Non-neoplastic tissue specimens resected well outside the tumour border served as controls. COX-2 expression was found to be markedly enhanced in the neoplastic epithelium compared with controls. This was paralleled by a significantly higher expression of IL-1beta, IL-6 and p65. Serial sections revealed consistent cellular colocalizations of respective antigens in the neoplastic epithelium. Statistically, a significant correlation between expression of COX-2 and IL-1beta, IL-6 and p65 was found. Comparable results were obtained for stromal cells like macrophages and myofibroblasts. Further examination of nuclear extracts from CRC-specimens by western blotting confirmed a higher content of p65 protein compared with non-neoplastic control tissues. Therefore, our study provides evidence for an association between expression of COX-2 and IL-1beta, IL-6 and p65 in human CRC. The results are consistent with the thesis that proinflammatory cytokines such as IL-1beta and IL-6 may be accountable for the overexpression of COX-2 in CRC. Finally, the study corroborates a role for NF-B in the control of COX-2 gene transcription in CRC. Given an antiapoptotic role for COX-2 in tumour cells, inhibition of NF-B may offer an important strategy to interfere with the development and progression of CRC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M.-T. Lin, C.-Y. Zuon, C.-C. Chang, S.-T. Chen, C.-P. Chen, B.-R. Lin, M.-Y. Wang, Y.-M. Jeng, K.-J. Chang, P.-H. Lee, et al. Cyr61 Induces Gastric Cancer Cell Motility/Invasion via Activation of the Integrin/Nuclear Factor-{kappa}B/Cyclooxygenase-2 Signaling Pathway Clin. Cancer Res., August 15, 2005; 11(16): 5809 - 5820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ross, B. V. S. Kallakury, C. E. Sheehan, H. A. G. Fisher, R. P. Kaufman Jr., P. Kaur, K. Gray, and B. Stringer Expression of Nuclear Factor-{kappa}B and I{kappa}B{alpha} Proteins in Prostatic Adenocarcinomas: Correlation of Nuclear Factor-{kappa}B Immunoreactivity with Disease Recurrence Clin. Cancer Res., April 1, 2004; 10(7): 2466 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mulshine, J. C. Atkinson, R. O. Greer, V. A. Papadimitrakopoulou, C. Van Waes, S. Rudy, J. W. Martin, S. M. Steinberg, D. J. Liewehr, I. Avis, et al. Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia Clin. Cancer Res., March 1, 2004; 10(5): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yamanaka, T. Morisaki, H. Nakashima, A. Tasaki, M. Kubo, H. Kuga, C. Nakahara, K. Nakamura, H. Noshiro, T. Yao, et al. Interleukin 1{beta} Enhances Invasive Ability of Gastric Carcinoma through Nuclear Factor-{kappa}B Activation Clin. Cancer Res., March 1, 2004; 10(5): 1853 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saha, K. R. Sekhar, C. Cao, J. D. Morrow, H. Choy, and M. L. Freeman The Antiangiogenic Agent SU5416 Down-Regulates Phorbol Ester-Mediated Induction of Cyclooxygenase 2 Expression by Inhibiting Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activity Cancer Res., October 15, 2003; 63(20): 6920 - 6927. [Abstract] [Full Text] [PDF]
|
|